Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026)
Molecular Partners Ag's (MOLN) quarterly Change in Receivables came in at $1.2 million in Q2 2026, up 179.81% year-over-year from $440879.9 in Q2 2025, and up 297.95% quarter-over-quarter from -$623178.3 in Q1 2026.
Analysis
Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Receivables for 7 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Change in Receivables rose 179.81% year-over-year to $1.2 million in Q2 2026; TTM through Jun 2026 was $2.8 million, a 1554.71% increase from a year earlier, with the FY2025 full-year figure at $584972.3, up 248.31% from the prior year.
- Change in Receivables was $1.2 million for Q2 2026 at Molecular Partners Ag, up from -$623178.3 in the prior quarter.
- Over five years, Change in Receivables peaked at $24.6 million in Q1 2022 and troughed at -$1.8 million in Q1 2025.
- A 5-year average of $1.5 million and a median of $302369.0 in 2023 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables slumped 185.34% in 2024 and jumped 3213.37% in 2025, its largest moves.
- Over 5 years, Change in Receivables stood at $726615.3 in 2022, then slumped by 131.5% to -$228853.0 in 2023, then soared by 599.3% to $1.1 million in 2024, then tumbled by 70.44% to $337815.8 in 2025, then jumped by 265.17% to $1.2 million in 2026.
- The last three Change in Receivables figures came in at $1.2 million (Q2 2026), -$623178.3 (Q1 2026), and $337815.8 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | 1.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Mn |
| Mar 31, 2026 | -623,178.28 |
| Dec 31, 2025 | 337,815.84 |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 440,879.93 |
| Mar 31, 2025 | -1.83 Mn |
| Dec 31, 2024 | 1.14 Mn |
| Sep 30, 2024 | 56,556.15 |
| Jun 30, 2024 | -227,793.46 |
| Mar 31, 2024 | -1.36 Mn |
| Dec 31, 2023 | -228,852.96 |
| Sep 30, 2023 | -295,491.82 |
| Jun 30, 2023 | 266,922.13 |
| Mar 31, 2023 | -766,544.27 |
| Dec 31, 2022 | 726,615.34 |
| Sep 30, 2022 | 1.01 Mn |
| Jun 30, 2022 | 869,051.25 |
| Mar 31, 2022 | 24.64 Mn |
| Dec 31, 2021 | -22.42 Mn |
| Sep 30, 2021 | 2.52 Mn |